Jane Osbourn joins Mogrify Board

British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.

Osbourn has over 30 years’ experience in biologics discovery and development. Most recently, she was Vice President for Research and Development and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology. She has made a significant contribution to the discovery and development of eight marketed drugs, including Humira and Benlysta. She is also Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and was awarded an OBE this year for services to drug discovery, development and biotechnology. She holds a doctorate from the John Innes Institute in Norwich, UK and a first-class degree in natural sciences from the University of Cambridge.
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.